Neoadjuvant Pembrolizumab + Epacadostat Prior to Curative Surgical Care for Squamous Cell Carcinoma of the Head and Neck
Status:
Withdrawn
Trial end date:
2018-11-07
Target enrollment:
Participant gender:
Summary
The KEO study is a single arm phase II trial including 44 patients with T1N1-2B, T2N0-N2B
head and neck squamous cell carcinoma (HNSCC) eligible for curative-intent resection (+/-
adjuvant therapy), who receive neo-adjvuant pembrolizumab + epacadostat.
The primary objective of this study is to determine rate of major treatment effect (MTE) to
neoadjuvant pembrolizumab+epacostat immunotherapy in SCCHN compared to historic data with
neoadjuvant pembrolizumab alone.